Economic Evaluation of a Novel Treatment of Attention-Deficit/Hyperactivity Disorder in US Motor Vehicle Drivers

Economic Evaluation of a Novel Treatment of Attention-Deficit/Hyperactivity Disorder in US Motor Vehicle Drivers

**Background:** Attention-deficit/hyperactivity disorder (ADHD) affects approximately 4.4% of US adults. ADHD is associated with high-risk driving behavior and costly motor vehicle accidents. DYANAVEL XR (DXR) (Tris Pharma, Inc.) is a once-daily fast-acting amphetamine developed for ADHD treatment....

Full description

Saved in:
Bibliographic Details
Main Authors: Jacie T. Cooper, John E. Schneider, Jim Potenziano, David S. Fam
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2024-09-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.121305
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items